GlassScriptPhysician profile
Michael A Scherlag
NPI 1578550505
$8,772.53
in general payments reported to CMS, 2019-2025
19 companies · $750 in 2025
The $750 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,978 · 2020: $295 · 2021: $544 · 2022: $304 · 2023: $473 · 2024: $430 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,857.46 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $1,100.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $596.36 | 2020-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $435.98 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $318.34 | 2019-2025 | Wainua, Farxiga |
| Novartis Pharmaceuticals Corporation | $296.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $277.97 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.76 | 2019-2025 | Jardiance |
| Pfizer INC. | $167.98 | 2025 | |
| Medtronic, INC. | $117.59 | 2021-2023 | Onyx Frontier |
| Bayer Healthcare Pharmaceuticals INC. | $117.32 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $69.49 | 2021 | |
| Abbott Laboratories | $61.19 | 2023 | Cardiomems, Mitraclip |
| Kestra Medical Technology Services, INC. | $44.68 | 2023-2024 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $23.92 | 2024 | Arcalyst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $19.44 | 2025 | Watchman Flx |
| Lilly USA, LLC | $18.21 | 2025 | Zepbound, Mounjaro |
| Irhythm Technologies, INC. | $17.45 | 2024 | Zio Monitor, Zio Xt Patch |
| Novo Nordisk INC | $15.05 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Scherlag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.